VTVT · Company research

vTv Therapeutics Inc. Class A Common Stock (VTVT): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

16records availableHealthcare

Stock News & Events data

Database-backed records only

16 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
(VTVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily(VTVT) Price Dynamics and Execution-Aware Positioning Stock Traders DailyView source ↗Stock Traders DailyOct 15, 2026neutral00.6
vTv Therapeutics' (VTVT) "Buy" Rating Reiterated at BTIG Research - MarketBeatvTv Therapeutics' (VTVT) "Buy" Rating Reiterated at BTIG Research MarketBeatView source ↗MarketBeatOct 14, 2026neutral00.6
VTVT Reiterates Rating by BTIG - Price Target Maintained at $57 - GuruFocusVTVT Reiterates Rating by BTIG - Price Target Maintained at $57 GuruFocusView source ↗GuruFocusOct 14, 2026neutral00.6
vTv Therapeutics Inc. (VTVT) Stock Price, News, Quote & History - Yahoo! Finance CanadavTv Therapeutics Inc. (VTVT) Stock Price, News, Quote & History Yahoo! Finance CanadaView source ↗Yahoo! Finance CanadaOct 11, 2026neutral00.6
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 - Stock TitanvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 Stock TitanView source ↗Stock TitanOct 10, 2026neutral00.6
Three parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment. - Stock TitanThree parties report shared voting power over vTv Therapeutics (VTVT) shares in a passive stake amendment. Stock TitanView source ↗Stock TitanOct 8, 2026neutral00.6
vTv Therapeutics stock jumps on FDA orphan drug status - Yahoo FinancevTv Therapeutics stock jumps on FDA orphan drug status Yahoo FinanceView source ↗Yahoo FinanceOct 8, 2026neutral00.6
A cellist will join diabetes experts to discuss low blood sugar in type 1 diabetes - Stock TitanA cellist will join diabetes experts to discuss low blood sugar in type 1 diabetes Stock TitanView source ↗Stock TitanOct 6, 2026neutral00.6
Behavioral Patterns of VTVT and Institutional Flows - Stock Traders DailyBehavioral Patterns of VTVT and Institutional Flows Stock Traders DailyView source ↗Stock Traders DailyOct 5, 2026neutral00.6
Vtv Theraptcs Cl A (VTVT-Q) Stock Price and News - The Globe and MailVtv Theraptcs Cl A (VTVT-Q) Stock Price and News The Globe and MailView source ↗The Globe and MailOct 1, 2026neutral00.6
vTv Therapeutics (VTVT) Holds Above $30 as Shares Edge 0.50% Higher - Breadth Thrust - siam.invTv Therapeutics (VTVT) Holds Above $30 as Shares Edge 0.50% Higher - Breadth Thrust siam.inView source ↗siam.inSep 28, 2026neutral00.6
Behavioral Patterns of VTVT and Institutional Flows - Stock Traders DailyBehavioral Patterns of VTVT and Institutional Flows Stock Traders DailyView source ↗Stock Traders DailySep 25, 2026neutral00.6
vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened - MarketBeatvTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened MarketBeatView source ↗MarketBeatSep 23, 2026neutral00.6
vTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue - Simply Wall StreetvTv Therapeutics (VTVT) Stock Rises Despite Widening Losses And Zero Revenue Simply Wall StreetView source ↗Simply Wall StreetAug 8, 2026neutral00.6
VTVT Forecast — Price Target — Prediction for 2027 - TradingViewVTVT Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 25, 2026neutral00.6
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo FinancevTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable Yahoo FinanceView source ↗Yahoo FinanceMay 15, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.